Drug safety watchdog has issued a new drug recall method, which
encourages pharmaceutical manufacturers to recall unsafe drugs
voluntarily.
The regulation, promulgated Monday by the State Food and Drug
Administration (SFDA), says that enterprises, which voluntarily
recall unsafe drugs, will be subject to lower, or even be exempted
from, administrative punishment.
Those, who are aware of problems with their drugs but fail to
issue voluntary recalls, will face heavy fines or even be deprived
of drug manufacturing licenses, Yan Jiangying, spokesperson of the
SFDA, told a press conference Wednesday.
China has witnessed a series of drug safety scandals over the
past years. Yan said most drug recalls in the past in China were
compulsory recalls issued by the government.
"The new recall methods emphasize the primary responsibility of
pharmaceutical manufacturers in drug safety," Yan said.
According to the regulation, manufacturers must set up and
improve their quality monitoring systems, promptly analyze
information and feedback from hospitals, retailers and users, and
to investigate and evaluate potentially unsafe drugs.
It classifies the problem drugs that must be recalled into three
categories, with the first being potentially fatal and harmful
drugs, which must be recalled within 24 hours of the recall
announcement.
The second category is drugs that may cause temporary or
reversible health problems and producers have two days to recall
these.
The third category involves drugs that must be recalled within
three days for reasons other than safety, such as improper
packaging.
The move by the SFDA comes in the wake of pressure on the
Chinese government to overhaul the country's food and drug safety
system.
One of the most notorious cases of substandard drugs was that of
Anhui Huayuan Worldbest Biology Pharmacy Co., whose antibiotic
injections had been blamed for six deaths last year.
The problem injections, produced in June and July last year, was
found to be not properly sterilized, with both sterilization
temperature and time being below the state-required safety level.
The producer was then given two weeks by the SFDA to retrieve all
its problem drugs.
(Xinhua News Agency December 12, 2007)